- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/54 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
Patent holdings for IPC class C07D 231/54
Total number of patents in this class: 305
10-year publication summary
|
23
|
21
|
22
|
29
|
23
|
14
|
17
|
19
|
7
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Arena Pharmaceuticals, Inc. | 365 |
23 |
| Gilead Sciences, Inc. | 2032 |
15 |
| Reata Pharmaceuticals, Inc. | 123 |
13 |
| Janssen Pharmaceutica N.V. | 3394 |
9 |
| Bristol-myers Squibb Company | 4880 |
8 |
| Novartis AG | 10744 |
7 |
| Bayer Pharma AG | 1053 |
6 |
| Array BioPharma Inc. | 498 |
6 |
| Taro Pharmaceuticals Inc. | 34 |
6 |
| Merck Sharp & Dohme LLC | 3751 |
6 |
| F. Hoffmann-La Roche AG | 7947 |
5 |
| Abbvie Inc. | 1800 |
5 |
| Boehringer Ingelheim International GmbH | 4642 |
4 |
| Merck Patent GmbH | 5815 |
4 |
| Duke University | 3069 |
4 |
| Esanex, Inc. | 8 |
4 |
| Bioardis, LLC | 32 |
4 |
| Biolexis Therapeutics, Inc. | 8 |
4 |
| Glaxo Group Limited | 4063 |
3 |
| Pfizer Inc. | 3371 |
3 |
| Other owners | 166 |